登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IL-2 >GMP-L02H14GB01

CytoPak™ GMP Human IL-2 Protein

No equivalent PG product available.
热门推荐产品:配套残留检测试剂盒

IL-2 Product Show

CytoPak™ GMP Human IL-2 Protein is packaged in sterile closed containers that can be readily incorporated into ex vivo clinical production processes. The bag utilizes medical grade multilayer film with two weldable options. The outlet weldable tube contains a proximal TPE section (1/8’’ ID x 1/4’’ OD) and a distal PVC section (3/32’’ ID x 5/32’’ OD). The liquid state and closed-system packaging of CytoPak™ GMP Human IL-2 Protein can be directly welded to GMP media bags resulting in safety and user-friendliness by bypassing the reconstitution step during manufacture.

优势特色(Features)

  1. Closed System Process
  2. Minimized Manual Touchpoints
  3. Ready-to-Use Format
  4. Enhanced Efficiency
  5. Weldable Tubing
  6. Designed under ISO 9001:2015 and ISO 13485:2016
  7. Manufactured and QC tested under a GMP compliance factory
  8. Animal-Free materials
  9. Beta-lactam materials free
  10. Batch-to-batch consistency

表达区间及表达系统(Source)

CytoPak GMP Human IL-2 Protein (GMP-L02H14GB01) is expressed from E. coli cells. It contains AA Ala 21 - Thr 153 (Accession # P60568-1).

Predicted N-terminus: Met

蛋白结构(Molecular Characterization)

IL-2 Structure

This protein carries no "tag".

The protein has a calculated MW of 15.4 kDa. The protein migrates as 16 kDa±2 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 5.0 EU/mL by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.1 ng/μg of protein tested by qPCR.

无菌(Sterility)

The sterility testing was performed by membrane filtration method described in USP<71> and Ph. Eur. 2.6.1.

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Supplied as 0.2 μm filtered solution in phosphate with protectants.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Upon receipt, store it immediately at -70°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -70°C for 24 months;
  2. Can be stored up to 1 month at -20°C;
  3. Can be stored up to 1 week at 2-8°C.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

IL-2 SDS-PAGE

CytoPak GMP Human IL-2 Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-CELL BASE

IL-2 CELL

CytoPak GMP Human IL-2 Protein (Cat. No.GMP-L02H14GB01) stimulates proliferation of CTLL-2 cells. The specific activity of CytoPak GMP Human IL-2 Protein is ≥1.20 x 10^7 IU/mg, which is calibrated against human Interleukin-2 China National Standard (NIFDC code: 270008) (QC tested). China National Institutes for Food and Drug Control (NIFDC) Standard was prepared and calibrated against human IL-2 WHO International Standard (NIBSC code: 86/500) by NIFDC.

Protocol

 

稳定性(Stability)

IL-2 STABILITY

The Cell based assay shows that CytoPak GMP Human IL-2 Protein (Cat. No. GMP-L02H14GB01) is stable at 25°C for 65 hours.

IL-2 STABILITY

The Cell based assay shows that CytoPak GMP Human IL-2 Protein (Cat. No. GMP-L02H14GB01) is stable after freezing and thawing 3 times.

MANUFACTURING SPECIFICATIONS

ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP <92> Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.


ACROBiosystems Quality Management System Contents:

  1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.
  2. Animal-Free materials
  3. Materials purchased from the approved suppliers by QA
  4. ISO 5 clean rooms and automatic filling equipment
  5. Qualified personnel
  6. Quality-related documents review and approve by QA
  7. Fully batch production and control records
  8. Equipment maintenance and calibration
  9. Validation of analytical procedures
  10. Stability studies conducted
  11. Comprehensive regulatory support files

Request For Regulatory Support Files(RSF)  Request For DMF


ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

  1. SDS-PAGE
  2. Protein content
  3. Endotoxin level
  4. Residual Host Cell DNA content
  5. Residual Host Cell Protein content
  6. Biological activity analysis
  7. Microbial testing
  8. Mycoplasma testing
  9. In vitro virus assay
  10. Batch-to-batch consistency


DISCLAIMER

ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for direct human use.

TERMS AND CONDITIONS

All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.


ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCAHSE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

 

前沿进展

Seleno-chitooligosaccharide-induced modulation of intestinal barrier function: Role of inflammatory cytokines, tight junction proteins, and gut microbiota in mice
He, Jin, Chen et al
J Appl Biomed (2025) 23 (1), 45-55
Abstract: This study aimed to explore the function of Seleno-chitooligosaccharide (SOA) on the intestinal barrier through regulation of inflammatory cytokines, tight junction protein, and gut microbiota in mice. The results of ELISA assay demonstrated that SOA significantly increased the levels of IL-2, IL-10, and IFN-γ in serum and ileum. Meanwhile, SOA increased the levels of IL-4 in the ileum (p < 0.05). In addition, Diamine Oxidase (DAO) concentration was decreased in ileum by SOA treatments (p < 0.05). The administration of SOA significantly upregulated the expression of ZO-1 and Occludin in the ileum (p < 0.05). By 16S rDNA sequencing, reduced ratio of Bacillota/Bacteroidota was observed in SOA treated mice. Within the phylum of Bacteroidota, SOA increased the relative abundance of Deferribacterota, uncultured Bacteroidales bacterium, and Bacteroides. Within the phylum of Bacillota, increased relative abundance of Erysipelatoclostridium and Lachnoclostridium, and reduced relative abundance of Ruminococcaceae UCG-010 were observed with SOA supplement. In summary, SOA has the potential to modulate the function of intestinal barrier function and prevent intestinal diseases.
Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma
Jin, Jia, Xia et al
Front Immunol (2025) 16, 1557006
Abstract: Tumor infiltrating lymphocytes (TILs) therapy has been proved for treatment of metastatic melanoma and is under investigation for other types of solid tumors. However, these successes are threatened by discontinued supply of GMP-grade anti-CD137 agonist, a key TIL preparation reagent. Therefore, exploring a GMP-adherent method for expanding endogenous TILs without anti-CD137 agonist is urgent. Toward this end, we aimed to establish an anti-CD137-independent and clinically feasible TIL expansion protocol to prepare TILs from under investigated sarcoma tumors.We collected resected tumors from patients and cut tissues into fragments. We used IL-2 and T-cell activator CD3/CD28 without anti-CD137 agonist to expand nonselected TILs in 2-3 weeks, then rapidly expanded them over 2 weeks. Their phenotypes were characterized using flow cytometry. Their antitumor activity was validated in vitro using cytotoxic T lymphocyte assays measuring CD107a on the TILs and the viability of tumor cells and in vivo using an autologous patient-derived xenograft (PDX) tumor model.We successfully expanded TILs in > 90% of collected samples. TILs generated preferentially increased CD8+ T cells but suppressed CD4+ T cells. A small portion of TILs were resident memory T cells. The expanded TILs reduced autologous tumor cells by 37.5% within 24 hours. Infusion of TILs in mice bearing autologous PDX tumors strongly inhibited liposarcoma growth. FDA has approved use of this GMP-feasible protocol in our clinical trial (IND 30562).It is feasible to generate antitumor TILs using CD3/CD28 activator to replace the unavailable anti-CD137 agonist. Our study supports the further development of TIL-based therapy.Copyright © 2025 Jin, Jia, Xia, Gordon, Ludwig, Somaiah and Li.
Effects of lipopolysaccharide administration on thymus damage, antioxidant capacity and immune function in weaned piglets
Bai, Jiang, Li et al
J Vet Res (2025) 69 (1), 111-119
Abstract: Piglets are vulnerable to stress during weaning because of changes in the feeding environment, nutrients, and other growth-impacting conditions. In this study, stress injury was modelled by continuous intraperitoneal injection of lipopolysaccharide (LPS) and was used to investigate the dynamics of antioxidant indices and immunoinflammatory factors in the piglet thymus.Forty-eight weaned piglets were divided into an LPS group and a control group. One group was injected with LPS solution (100 μg/kg) and the other with sterile saline daily. The experiment ran over 13 days, and six piglets from each group were euthanised for necropsy on days 1, 5, 9 and 13. Thymic tissues were collected, and the antioxidant indices and mRNA expression levels of related genes were measured by enzyme activity assay and reverse-transcription quantitative PCR.In the LPS group, catalase activities were significantly increased on days 1 and 5, that of superoxide dismutase was significantly higher on day 9 and glutathione activity was elevated throughout. Messenger RNA (mRNA) expression of the toll-like receptor 4 (TLR4) pathway, interleukin (IL) 6, and IL-2 increased in the thymus on day 1. By day 5, the mRNA expression of the TLR pathway, the janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, the kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, tumour necrosis factor α, IL-10, IL-6 and IL-2 were decreased. On day 13, the mRNA expression levels of the TLR4 and Keap1/Nrf2 pathways, TNF-α, IL-10 and IL-6 increased again.Continuous LPS induction led to high activation of the thymic immune system in piglets during the prophase. However, this activation was accompanied by atrophy and immunosuppression mid-experiment. Nevertheless, the immune function gradually recovered in the later stages.© 2025 Lingna Bai et al., published by Sciendo.
Markers of T Lymphocyte Activation in Children With Kawasaki Disease: An Experimental Study From North India
Sharma, Vignesh, Mondal et al
Int J Rheum Dis (2025) 28 (4), e70191
Abstract: The exact pathogenesis of Kawasaki disease (KD) is unknown despite extensive research in the area. Several studies have also implicated CD8+ T lymphocytes in the pathogenesis of KD. However, studies on the activation status of T lymphocytes have shown conflicting results.In this prospective study, early (CD69) and late activation (HLA-DR) markers were assessed in T lymphocytes by flow cytometry. We assessed serum levels of soluble CD25 (sCD25) by enzyme-linked immunosorbent assay. We compared these activation markers between children with KD (n = 10), febrile controls (n = 9), and healthy controls (n = 10). Furthermore, we studied the HLA-DRA and HLA-DRB gene expression in subgroups of KD with or without coronary artery aneurysms (CAAs).A significantly higher percentage of CD69 in CD3+ and CD3 + CD4+ T lymphocytes was noted in KD and febrile controls compared with healthy controls. We found no significant increase in late activation marker HLA-DR in CD3, CD3 + CD4+, and CD3 + CD8+ lymphocytes between KD, febrile, and healthy controls. We observed higher levels of sCD25 in KD and febrile controls than in healthy controls. Longitudinal follow-up in KD showed a decreasing trend of CD69 expression in CD3 + CD8+ lymphocytes and sCD25 levels over time. HLA-DRA and HLABRB expression was comparable between children with CAAs and those without CAAs.Our study showed early but not late activation of T lymphocytes in children with KD. Markers of lymphocyte activation do fall with subsidence of systemic inflammation following intravenous immunoglobulin therapy in KD.© 2025 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Showing 1-4 of 91349 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
法规支持文档(RSF)
一级-产品资质文档(免费)
二级-独特的质量和全性文档(付费)
点击咨询和申请
IL-2靶点信息
英文全称:Interleukin-2
中文全称:白细胞介素-2
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:39详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细
相关产品
View All IL-2

消息提示

请输入您的联系方式,再点击提交!

确定